CBLL
CBLLHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeCBLL operates as a medical technology company in the United States. Valued at $948.7M, CBLL is a small-cap name in its sector. It develops the Ceribell System, a novel and point-of-care EEG platform specifically designed to address the unmet needs of patients in the acute care setting.
Market Cap
$948.7M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-15.32
EPS (TTM)
$-1.76
EPS (Fwd)
$-1.61
ROE
-43.9%
ROA
-23.4%
Cash
$129.3M
Total Debt
$21.9M
Free CF
-$33.0M
52W Change
108.4%
Annual Financials
Cash vs Debt
Where CBLL stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, CBLL finished 26.12% above its 150-day moving average ($19.49) and 25.54% above its 200-day moving average ($19.58). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is CBLL overbought or oversold?
At the September 2, 2026 close, CBLL's RSI(14) was 66.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $129.3M in cash and $21.9M in debt, CBLL maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow is running at -$33.0M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -43.9% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $25.9M (2022) to $89.1M (2025), reflecting a 244% increase over the period.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing CBLL.